<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Why Moderna (MRNA) Shares Are Falling Today — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Why Moderna (MRNA) Shares Are Falling Today</h2>
    <div class="badge">2025-09-08T18:26:30+00:00</div>
    <ul>
      <li>Moderna is down 42.9% since the beginning of the year, and at $23.99 per share, it is trading 69.8% below its 52-week high of $79.51 from September 2024.</li>
<li>Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 4.8% in the afternoon session after competitors Pfizer and BioNTech announced positive topline results for their updated 2025-2026 COVID-19 vaccine formula.</li>
<li>What Is The Market Telling Us Moderna’s shares are extremely volatile and have had 50 moves greater than 5% over the last year.</li>
<li>The previous big move we wrote about was 12 days ago when the stock gained 3.6% on the news that the company announced it received U.S.</li>
<li>Food and Drug Administration (FDA) approval for its updated COVID-19 vaccines for the 2025-2026 season.</li>
<li>Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an investment worth $441.46.</li>
<li>At the conference, CEO Stéphane Bancel outlined strategic priorities but also noted the company faces market uncertainties and is targeting cash flow break-even by 2028.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Why Moderna (MRNA) Shares Are Falling Today\n• Moderna is down 42.9% since the beginning of the year, and at $23.99 per share, it is trading 69.8% below its 52-week high of $79.51 from September 2024.\n• Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 4.8% in the afternoon session after competitors Pfizer and BioNTech announced positive topline results for their updated 2025-2026 COVID-19 vaccine formula.\n• What Is The Market Telling Us Moderna’s shares are extremely volatile and have had 50 moves greater than 5% over the last year.\n• The previous big move we wrote about was 12 days ago when the stock gained 3.6% on the news that the company announced it received U.S.\n• Food and Drug Administration (FDA) approval for its updated COVID-19 vaccines for the 2025-2026 season.\n• Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an investment worth $441.46.\n• At the conference, CEO Stéphane Bancel outlined strategic priorities but also noted the company faces market uncertainties and is targeting cash flow break-even by 2028." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/why-moderna-mrna-shares-falling-182630851.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>